Medigene AG
MDG1
Kedudukan dalam Saham
#35330
Medigene AG is a German biotechnology company primarily focused on innovating T... Medigene AG is a German biotechnology company primarily focused on innovating T cell immunotherapies to treat various cancers. Their developmental pipeline includes personalized T cell therapies, particularly T cell receptor-modified T cells, which are progressing through clinical stages to tackle significant unmet medical requirements. Additionally, the firm researches dendritic cell vaccines and T cell-specific monoclonal antibodies. Outside of its oncology efforts, Medigene is actively engaged in developing and bringing to market RhuDex for uses within hepatology and gastroenterology. A key strategic alliance exists with 2seventy bio, Inc., centered on advancing T cell receptors. The company also maintains research collaborations with the Université de Montréal and Cytovant Sciences Co. Ltd., investigating new cancer antigens for immunotherapy applications. Medigene's global presence encompasses operations across Europe, the United States, Asia, and various other international territories. Founded in 1994, the company's headquarters are located in Munich, Germany.
Harga Saham
$0.14942078
Disegerakkan terakhir: 2025-05-15
Modal Pasaran
$3.86M
Perubahan (1 hari)
0.10%
Perubahan (1 tahun)
39.97%
Negara
DE
Perdagangan Medigene AG (MDG1)
Kategori
Healthcare
Modal pasaran bagi Medigene AG(MDG1)
Modal Pasaran: $3.86M
Sehingga October 2026, Medigene AG mempunyai modal pasaran sebanyak $3.86M. Ini menjadikan Medigene AG syarikat ke-35330th paling bernilai di dunia mengikut data kami. Kapitalisasi pasaran ialah nilai keseluruhan saham syarikat tersenarai yang berada dalam edaran dan lazimnya digunakan untuk menilai nilai syarikat tersebut.
Sejarah modal pasaran Medigene AG dari 2007 hingga 2026
MDG1 berbanding dengan 5 teratas yang paling popular stocks
